HK18297A - (r)-3-methoxy-4- 1-methyl-5-(2-methyl-4,4,4-trifluorobutylcarbamoyl)indol-3-ylmethyl -n-(2-methylsulphonyl)benzamide in crystalline form - Google Patents

(r)-3-methoxy-4- 1-methyl-5-(2-methyl-4,4,4-trifluorobutylcarbamoyl)indol-3-ylmethyl -n-(2-methylsulphonyl)benzamide in crystalline form Download PDF

Info

Publication number
HK18297A
HK18297A HK18297A HK18297A HK18297A HK 18297 A HK18297 A HK 18297A HK 18297 A HK18297 A HK 18297A HK 18297 A HK18297 A HK 18297A HK 18297 A HK18297 A HK 18297A
Authority
HK
Hong Kong
Prior art keywords
methyl
methoxy
trifluorobutylcarbamoyl
benzamide
indol
Prior art date
Application number
HK18297A
Other languages
German (de)
English (en)
French (fr)
Inventor
Watson Cuthbert Murray
Original Assignee
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Limited filed Critical Astrazeneca Uk Limited
Publication of HK18297A publication Critical patent/HK18297A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK18297A 1991-09-05 1997-02-13 (r)-3-methoxy-4- 1-methyl-5-(2-methyl-4,4,4-trifluorobutylcarbamoyl)indol-3-ylmethyl -n-(2-methylsulphonyl)benzamide in crystalline form HK18297A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919119001A GB9119001D0 (en) 1991-09-05 1991-09-05 Pharmaceutical agents

Publications (1)

Publication Number Publication Date
HK18297A true HK18297A (en) 1997-02-13

Family

ID=10700953

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18297A HK18297A (en) 1991-09-05 1997-02-13 (r)-3-methoxy-4- 1-methyl-5-(2-methyl-4,4,4-trifluorobutylcarbamoyl)indol-3-ylmethyl -n-(2-methylsulphonyl)benzamide in crystalline form

Country Status (21)

Country Link
US (2) US5352694A (enExample)
EP (1) EP0531078B1 (enExample)
JP (1) JP2914414B2 (enExample)
KR (1) KR100254710B1 (enExample)
AT (1) ATE138910T1 (enExample)
AU (1) AU646587B2 (enExample)
CA (1) CA2076722A1 (enExample)
CZ (1) CZ281999B6 (enExample)
DE (1) DE69211258T2 (enExample)
DK (1) DK0531078T3 (enExample)
FI (1) FI102372B1 (enExample)
GB (2) GB9119001D0 (enExample)
HK (1) HK18297A (enExample)
HU (2) HU213410B (enExample)
IL (1) IL102856A (enExample)
NO (1) NO178370C (enExample)
NZ (1) NZ244016A (enExample)
RU (1) RU2095348C1 (enExample)
SK (1) SK267092A3 (enExample)
TW (1) TW302359B (enExample)
ZA (1) ZA926374B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958780A (en) 1997-06-30 1999-09-28 Boston Advanced Technologies, Inc. Method for marking and identifying liquids
GB9726735D0 (en) * 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
US6149914A (en) * 1999-07-12 2000-11-21 Patel; Jitendra Rambhai Asthma treatment
TWI353979B (en) * 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
CN101022796B (zh) 2004-07-14 2013-02-27 炎症研究中心有限公司 抑制肿瘤转移的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524152A (en) * 1982-12-30 1985-06-18 Pennwalt Corporation 1-Cyano-3-(fluoroalkyl)guanidines for lowering blood pressure
GB8623429D0 (en) * 1985-10-17 1986-11-05 Ici America Inc Carboximide derivatives
MY103259A (en) * 1987-04-15 1993-05-29 Ici America Inc Aliphatic carboxamides
GB8906032D0 (en) * 1988-04-14 1989-04-26 Ici America Inc Hetera-aliphatic carboxamides
GB8927981D0 (en) * 1989-12-11 1990-02-14 Ici Plc Carbamoyl derivative
GB9026425D0 (en) * 1990-12-05 1991-01-23 Ici Plc Process
GB9026427D0 (en) * 1990-12-05 1991-01-23 Ici Plc Chemical process
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
GB9027018D0 (en) * 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds

Also Published As

Publication number Publication date
NO923467L (no) 1993-03-08
EP0531078B1 (en) 1996-06-05
US5352694A (en) 1994-10-04
IL102856A0 (en) 1993-01-31
NO178370C (no) 1996-03-13
DE69211258T2 (de) 1996-10-02
DK0531078T3 (da) 1996-10-14
AU646587B2 (en) 1994-02-24
TW302359B (enExample) 1997-04-11
NO923467D0 (no) 1992-09-04
HU9202660D0 (en) 1992-10-28
FI102372B (fi) 1998-11-30
NZ244016A (en) 1995-01-27
ZA926374B (en) 1993-03-05
ATE138910T1 (de) 1996-06-15
GB9216774D0 (en) 1992-09-23
NO178370B (no) 1995-12-04
SK279657B6 (sk) 1999-02-11
JPH05194385A (ja) 1993-08-03
AU2101292A (en) 1993-03-11
RU2095348C1 (ru) 1997-11-10
EP0531078A1 (en) 1993-03-10
HU213410B (en) 1997-06-30
CZ281999B6 (cs) 1997-04-16
US5466826A (en) 1995-11-14
IL102856A (en) 1996-12-05
FI102372B1 (fi) 1998-11-30
KR100254710B1 (ko) 2000-05-01
FI923869A0 (fi) 1992-08-28
HUT69696A (en) 1995-09-28
SK267092A3 (en) 1999-02-11
FI923869L (fi) 1993-03-06
CZ267092A3 (en) 1993-03-17
KR930005976A (ko) 1993-04-20
GB9119001D0 (en) 1991-10-23
JP2914414B2 (ja) 1999-06-28
DE69211258D1 (de) 1996-07-11
CA2076722A1 (en) 1993-03-06
HU210879A9 (en) 1995-09-28

Similar Documents

Publication Publication Date Title
JP2009035547A (ja) リモナバントの結晶多形の製造方法
US5354760A (en) Crystalline Tiagabine monohydrate, its preparation and use
JP4184666B2 (ja) カベルゴリンの結晶性形態ｉを調製するための方法
CA2031897C (en) Carbamoyl derivatives
EP0531078B1 (en) (R)-3-Methoxy-4- 1-methyl-5-(2-methyl-4,4,4-trifluorobutylcarbamoyl)indol-3-ylmethyl -N-(2-methylsulphonyl)benzamide in crystalline form
TWI518072B (zh) 塔適那偉（ａｔａｚａｎａｖｉｒ）硫酸氫鹽之製法及其新穎的形式
TWI499584B (zh) ４－｛３－［順－六氫環戊［ｃ］吡咯－２（１ｈ）－基］丙氧基｝苯甲醯胺鹽酸鹽之晶形及其合成方法及含彼之醫藥組合物
JPWO2001038330A1 (ja) 無水ミルタザピン結晶およびその製造方法
HK1003830B (en) Carbamoyl derivatives
KR100622512B1 (ko) 카베르골린의 결정형 ι의 제조 방법
MXPA03011728A (es) Formas cristalinas novedosas del acido 4-[4-[4- (hidroxidifenilmetil) -1-piperidinil] -1-hidroxibutil] -alfa, alfa -dimetilbencen acetico y su clorohidrato.
JPH0762002B2 (ja) シメチジン多形体ｂの製造法
EP1051398B1 (en) Thermodynamically stable form of (r)-3- (4-fluorophenyl) sulphonyl]amino] -1,2,3,4- tetrahydro -9h-carbazole -9-propanoic acid (ramatroban)
JPS63130570A (ja) ３，５−ジ第３級ブチル−４−ヒドロキシ桂皮酸アミド誘導体

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100901